Journal article
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
HemaSphere, Vol.6(7), pp.e745-e745
06/21/2022
DOI: 10.1097/HS9.0000000000000745
PMCID: PMC9263496
PMID: 35813099
Abstract
This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients’ (80.2%) index therapy occurred in third line (3L) (range, 3L–6L). Median follow-up from FL diagnosis was 9 years (range, 1–21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL.
Details
- Title: Subtitle
- A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
- Creators
- Gilles Salles - Memorial Sloan Kettering Cancer CenterStephen J. Schuster - University of PennsylvaniaLuca Fischer - Department of Internal Medicine III, LMU Hospital, Munich, GermanyJohn Kuruvilla - Princess Margaret Cancer CentrePiers E. M. Patten - King's College LondonBastian von Tresckow - University of Duisburg-EssenSonali Smith - University of ChicagoAna Jiménez Ubieto - Centro de Investigación Biomédica en RedKeith L. Davis - Health Economics, RTI Health Solutions, Research Triangle Park, NC, USASaurabh Nagar - Health Economics, RTI Health Solutions, Research Triangle Park, NC, USAJie Zhang - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAVamsi Bollu - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAEtienne Jousseaume - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USARoberto Ramos - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAYucai Wang - Mayo ClinicBrian K. Link - University of Iowa
- Resource Type
- Journal article
- Publication Details
- HemaSphere, Vol.6(7), pp.e745-e745
- DOI
- 10.1097/HS9.0000000000000745
- PMID
- 35813099
- PMCID
- PMC9263496
- NLM abbreviation
- Hemasphere
- ISSN
- 2572-9241
- eISSN
- 2572-9241
- Publisher
- Lippincott Williams & Wilkins
- Language
- English
- Date published
- 06/21/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359923002771
Metrics
19 Record Views